A radiogenomics application for prognostic profiling of endometrial cancer.

Journal: Communications biology
Published Date:

Abstract

Prognostication is critical for accurate diagnosis and tailored treatment in endometrial cancer (EC). We employed radiogenomics to integrate preoperative magnetic resonance imaging (MRI, n = 487 patients) with histologic-, transcriptomic- and molecular biomarkers (n = 550 patients) aiming to identify aggressive tumor features in a study including 866 EC patients. Whole-volume tumor radiomic profiling from manually (radiologists) segmented tumors (n = 138 patients) yielded clusters identifying patients with high-risk histological features and poor survival. Radiomic profiling by a fully automated machine learning (ML)-based tumor segmentation algorithm (n = 336 patients) reproduced the same radiomic prognostic groups. From these radiomic risk-groups, an 11-gene high-risk signature was defined, and its prognostic role was reproduced in orthologous validation cohorts (n = 554 patients) and aligned with The Cancer Genome Atlas (TCGA) molecular class with poor survival (copy-number-high/p53-altered). We conclude that MRI-based integrated radiogenomics profiling provides refined tumor characterization that may aid in prognostication and guide future treatment strategies in EC.

Authors

  • Erling A Hoivik
    Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway. Erling.Hoivik@uib.no.
  • Erlend Hodneland
    NORCE Norwegian Research Centre, Bergen, Norway. erlend.hodneland@uib.no.
  • Julie A Dybvik
    Department of Radiology, MMIV Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway.
  • Kari S Wagner-Larsen
    Department of Radiology, MMIV Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway.
  • Kristine E Fasmer
    Department of Radiology, MMIV Mohn Medical Imaging and Visualization Centre, Haukeland University Hospital, Bergen, Norway.
  • Hege F Berg
    Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Mari K Halle
    Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Ingfrid S Haldorsen
    Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, Bergen, Norway. Ingfrid.Haldorsen@uib.no.
  • Camilla Krakstad
    Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.